Kestra Medical names Daniel Finney VP of research and development

Kestra Medical Technologies (Nasdaq: KMTS) has appointed Daniel Finney as Vice President of Research and Development, adding him to the company's executive leadership team, according to a press release.

Finney succeeds Phillip D. Foshee, Jr., who led Kestra's research and development organization from 2016 until his recent retirement. Foshee oversaw the development of the company's ASSURE wearable cardioverter defibrillator during his tenure.

Finney most recently served as Kestra's Senior Director of New Product Development. He has more than 20 years of experience in Class III medical device development, engineering management, and project management. Before joining Kestra, he held product development roles at Stryker, Physio-Control, and Medtronic.

In his new role, Finney will lead research and development initiatives across Kestra's Cardiac Recovery System platform, including strategic partnerships and the application of artificial intelligence. The company said his priorities will be informed by clinical evidence, including findings from the ASSURE Clinical Evaluation Post-Approval Study, which it described as the largest prospective real-world study of wearable cardioverter defibrillators conducted to date.

"Research and development is central to advancing our mission and expanding the role of wearable protection for at-risk patients during critical periods of recovery," said Brian Webster, President and Chief Executive Officer.

You May Also Be Interested In

• TransMedics names new CFO and reiterates 2026 revenue guidance
• Shell sells New England power plant for $715M, buys Pennsylvania asset
• Nutex Health says stolen data published after cyberattack